Skip to main content


Fig. 1 | Arthritis Research & Therapy

Fig. 1

From: Experience with etanercept, tocilizumab and interleukin-1 inhibitors in systemic onset juvenile idiopathic arthritis patients from the BIKER registry

Fig. 1

Juvenile Disease Activity Score 10 (JADAS-10) remission (defined as JADAS ≤1) and JADAS minimal disease activity (defined as JADAS ≤3.8). The number of patient contributing to the calculation is given below the figure. TOC, tocilizumab; ETA, etanercept; IL-1i, interleukin-1 inhibitor; ACR, American College of Rheumatology

Back to article page